Femasys Targets Fertility and Women’s Health

Femasys Targets Fertility and Women’s Health

MPO's Sean Fenske speaks with Kathy Lee-Sepsick of Femasys about how the company is addressing infertility as well as preventing pregnancy.

By Sean Fenske, Editor-in-Chief01.06.22
In this episode of Medtech Matters, a podcast focused on the medical device manufacturing industry and the factors impacting it, we speak with Kathy Lee-Sepsick, founder and CEO of Femasys. She provides an overview of how the company’s technology is helping women who are dealing with infertility. She also speaks about a device that enables a non-surgical means of permanent birth control. Specifically, the following questions are addressed.

  • Can you please start off by giving us a little insight on what Femasys is?
  • So your technologies are at both end of the spectrum, addressing infertility and also helping to prevent pregnancy. Can you talk a bit about the FemaSeed and how it different from other available infertility technologies?
  • What is FemBlock and how does it work?
  • What is FemVue and how did it change the current standard for this type of medicine?
  • What’s next for Femasys? Where is the firm headed?

Listen to this episode and see what you think of the women’s health technologies from Femasys. If you’d like to share thoughts, ask questions, or suggest a future participant for Medtech Matters, please reach out to me at sfenske@rodmanmedia.com.

Listen to the podcast streaming via the player or get the podcast on the Medtech Matters channel via your preferred vendor of podcasts, such as Apple Podcasts (iTunes) or Spotify.

Click here to review other podcasts.